Email UpdatesThe field of psychedelic medicine has gained significant popularity over the past two to three years, with attention focused on uses for behavioral health disorders and even well-being.
Join this webinar to review the use of psychedelic substances and how they impact the brain and behavior. Specifically, we will discuss psilocybin (a.k.a. "magic mushrooms"), MDMA, and ketamine as new research shows positive impacts on various mental health and substance use disorders.
Additionally, it will discuss current regulatory issues and challenges from the perspective of what this means for practicing clinicians. Since the therapeutic psychedelics industry is expected to grow from $3.6 billion in 2021 to $8.3 billion in 2028, will psychedelics become mainstream in behavioral health?